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We herein report a case of invasive micropapillary carcinoma (IMPC) involving extensive lymph node metastasis
with no recurrence for over 7 years. A 41-year-old female presented with pain and a swelling mass in the left
axillary region, which had been present for several months. The tumor measured 1.6 cm in diameter in the
middle of upper area of the left breast. Based on the findings of a core needle biopsy the pathological diagnosis
was IMPC or mucinous carcinoma. The cytology of the left axillary lymph node was positive for metastatic carcinoma.
The patient underwent a left mastectomy and a left axillary dissection (level I to III). The postoperative pathological
diagnosis was IMPC with mucin production, and the number of metastatic lymph nodes was 59. The patient was given
adjuvant chemotherapy (four courses of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and four courses of
docetaxel), radiation for the left chest wall, supraclavicular and internal thoracic area, and then received tamoxifen for
5 years. The patient has remained recurrence-free for over 7 years. IMPC is known to be an aggressive histological
type associated with a high incidence of lymph node metastasis and a poor prognosis. It seems that long-term
survival was obtained by performing sufficient medical treatment. Prognostic factors other than the number of
lymph node metastases may also exist.
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Invasive micropapillary carcinoma (IMPC) was described
by Fisher as an invasive papillary cancer with an exfolia-
tive appearance [1]. Pettinato et al. reported an invasive
ductal carcinoma resembling ovarian serous carcinoma
as a ‘pseudopapillary carcinoma of the breast’ [2]. IMPC
was first reported by Siriaunkgul and Tavassoli in 1993
as a rare subtype of epithelial tumor of the breast [3].
The percentage of IMPC in all breast cancers is estimated
to be 1.7% to 2.7% [4,5]. IMPC is characterized by an
inside-out growth pattern forming a micropapillary or
tubular-alveolar arrangement [3], invasion to the lymph-
atic or vascular space and a high frequency of lymph node
metastasis [4,6-8].
IMPC is associated with a poor prognosis. Luna-More
et al. reported that of 27 patients with micropapillary* Correspondence: taketani@surg2.med.kyushu-u.ac.jp
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reproduction in any medium, provided the orcarcinoma, all of them had metastasis to axillary lymph
nodes. Twelve of these patients were followed-up, six of
whom died after an average of 22 months from the ini-
tial treatment [4].
We herein report a patient with IMPC who had 59
lymph node metastases, and who has remained free of
recurrence for over 7 years.Case presentation
The present case was a 41-year-old premenopausal
female at presentation. The patient had experienced pain
and a swelling mass in the left axilla for several months
before visiting a local doctor. A nodule was detected in
the middle of upper area of the left breast, and a core
needle biopsy was performed, which indicated a patho-
logical diagnosis of IMPC or mucinous carcinoma. The
cytology of the left axillary lymph nodes was positive for
metastatic carcinoma. The patient was referred to Kyushul Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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additional examinations.
A physical examination revealed that a 2 cm in diam-
eter hard mass was palpable in the AC area of the left
breast, and painful, hard lymph nodes were palpable in
the patient’s left axilla. The laboratory data showed a
high level of carbohydrate antigen 15-3 (CA15-3; 39.8
U/mL), but normal levels of carcinoembryonic antigen
(CEA; 2.0 ng/mL) and National Cancer Center-ST439
(NCC-ST439; 4.1 U/mL). Mammography showed focal
asymmetrical density in the left upper area in the left
mediolateral oblique position (Figure 1a). Ultrasonog-
raphy confirmed a lobulated, low- to iso-echoic nodule
with a high echo spot (Figure 1b). It was noted to be
21 mm in diameter and the border was unclear. The
ipsilateral axillary lymph nodes were swollen, the largestFigure 1 Imaging findings. (a) Mammography showed focal asymmetrica
position (arrow). (b) Ultrasonography confirmed the presence of a 21 mm
the border of which was unclear. (c) The ipsilateral axillary lymph nodes we
revealed a low enhanced mass with calcification in the middle of upper ar
subclavicular lymph nodes (right) were swollen. (e) MRI revealed a lobulate
breast.; CT, computed tomography; MRI, magnetic resonance imaging.of which was 32 mm in diameter (Figure 1c). A com-
puted tomography (CT) scan revealed that the low en-
hanced mass with calcification was in the middle of
upper area of the left breast (Figure 1d, left), and that
the ipsilateral axillary (Figure 1d, middle) and subclavi-
cular (Figure 1d, right) lymph nodes were swollen. There
were no findings of metastasis to the bone, liver or
lungs. Magnetic resonance imaging (MRI) revealed the
presence of a lobulated mass with high intensity in the
middle of upper area of the left breast, which was rein-
forced by gadolinium from the early phase (Figure 1e).
Based on these clinical and pathological findings, the pa-
tient was diagnosed to have an IMPC or mucinous carcin-
oma according to The Japanese Breast Cancer Society’s
General Rules for Clinical and Pathological Recording of
Breast Cancer [9] and the clinical stage was T1cN3aM0l density in the left upper area of the left mediolateral oblique
in diameter, lobulated, low- to iso-echoic area with a high echo spot,
re swollen, the largest of which was 32 mm in diameter. (d) A CT scan
ea of the left breast (left), and the ipsilateral axillary (middle) and
d mass with high intensity in the middle of upper area of the left
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Cancer Control (UICC) TNM Classification of Malignant
Tumors.
The patient underwent a left mastectomy and a left axil-
lary lymph node dissection (level I to III). A histopatho-
logical examination of the postoperative specimen showed
that the masses of the micropapillary component and
clusters of carcinoma cells were floating in extracellular
mucin pools. The histological diagnosis was IMPC with
mucin production (Figure 2). The histopathological find-
ings showed that the histological nuclear grade was 1
(nuclear atypia 2 and mitotic count 1). Fifty-nine lymph
nodes were diagnosed to be positive for carcinoma cells:
41 in level I, 12 in level II and six in level III. Lymph duct
and vessel invasion were not observed.
The immunohistochemical examination of the tumor
cells showed positivity for the estrogen receptor (ER;
Allred score, proportion score (PS) 4 + intensity score (IS)
2 = total score (TS) 6), and negative findings for the pro-
gesterone receptor (PgR; Allred score, PS 0 + IS 0 = TS 0)
and HER2 (score 0). The Ki-67 labeling index was 4.3%
(Figure 3).
The patient was treated with four courses of 5-
fluorouracil (5-FU), epirubicin and cyclophosphamide
(FEC) (5-FU 500 mg/m2, epirubicin 100 mg/m2, cyclo-
phosphamide 500 mg/m2) and four courses of docetaxel
(75 mg/m2) as adjuvant chemotherapy. Radiation therapyFigure 2 Pathological findings of H & E staining. (a,b) The primary lesio
floating in extracellular mucin pools. The histological diagnosis was IMPC w
magnification. (c,d) The metastatic lymph nodes showed similar pathologic
H & E, hematoxylin and eosin; IMPC, invasive micropapillary carcinoma.to the left chest wall and left cervical lesion (30.6 Gy/17 Fr
and 20 Gy/10 Fr) and the left internal thoracic lymph
nodes (50 Gy/25 Fr) was added. Thereafter, the patient
took tamoxifen for 5 years. The patient has remained free
from relapse for over 7 years after the surgery.
Discussion
We herein report a case of IMPC with no recurrence for
over 7 years despite the presence of extensive lymph
node metastasis. IMPC is a relatively new disease con-
cept, and is a rare subtype of epithelial tumor of the
breast. Most cases of IMPC are associated with nodal
metastases and a poor prognosis [6].
Metastases to axillary lymph nodes were seen in 71.2%
to 100% of IMPC cases [4,10,11]. The metastases were
typically multiple, with 51% of cases having three or
more positive lymph nodes [6], and the average number
of metastatic lymph nodes was 10.7 [11]. In addition,
lymphatic and vascular invasion has been reported in
33% to 67% of cases [3,4,8]. The number of nodal metas-
tases is associated with the prognosis in breast cancer,
regardless of the pathological type [12]. Nassar et al. re-
ported that the nodal status and skin involvement were
the only parameters that predicted a poor prognosis in
IMPC [6]. The prognosis of IMPC is significantly worse
than that of invasive ductal carcinoma of the scirrhous
type, and the 5-year overall survival rate of IMPC isn had a micropapillary component and clusters of carcinoma cells
ith mucin production. (a) × 40 and (b) × 100 and × 400 (in the square)
al features as the primary lesion. (c) × 40 and (d) × 100 magnification.
Figure 3 Immunohistochemical findings of ER, PgR, HER2, Ki-67 and CD24. (a) ER, (b) PgR, (c) HER2, (d) Ki-67 and (e) CD24. The cells were
positive for the ER and for CD24, negative for the PgR and HER2, and the Ki-67 labeling index was 4.3%. × 400 magnification. ER, estrogen
receptor; PgR, progesterone receptor.
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The 5-year recurrence rate was 62.6% for IMPC and
24.0% for scirrhous type tumors [11]. However, a recent
study showed that the disease-specific survival rate in
IMPC was similar to that of invasive ductal carcinoma
(91.9% versus 88%) [13]. In the report, IMPC with ER
negative and lymph node metastasis (≥4) was signifi-
cantly associated with worse 5-year disease-specific sur-
vival and 5-year overall survival [13].
The mechanism underlying the high incidence of
lymph node metastasis in IMPC has not been fully eluci-
dated. Ide et al. reported invasive carcinoma of the
breast comprising an IMPC component with signifi-
cantly higher incidence of lymph node metastasis and
invasion [14]. The tumors involving an IMPC compo-
nent, which is positive for hormone receptors and nega-
tive for HER2, tend to have a higher incidence of nodal
metastasis compared with their counterparts in all inva-
sive carcinomas. In contrast, lesions containing an IMPC
component and classified as hormone receptor negative
and HER2 positive have a lower incidence of nodal me-
tastasis [14]. CD24 has been reported as another markerfor IMPC related to lymph node metastasis. CD24 is an
adhesion mucin-like molecule, and its expression could
increase the ability of cancer cells to metastasize [15]
and invade lymph nodes [16]. In our case, the expression
of CD24 was positive in the epithelial lesion of the mam-
mary duct (Figure 3e). Our case was positive for both ER
and CD24, but negative for HER2, and the number of
lymph nodes with metastasis was 59, agreeing well with
the previous descriptions.
We had considered that the prognosis of this patient
would be very poor. However, more than 7 years have
passed since the patient’s surgery without relapse. We
were therefore interested in determining whether there
was any particular reason for the comparatively good
prognosis of this patient.
We had performed a complete axillary node dissection
from level I to III, and added standard chemotherapy
(anthracycline and taxane), endocrine therapy and radio-
therapy to the left chest wall and supraclavicular and in-
ternal thoracic regions in the present patient. Although
there was no contribution of axillary lymph node dissec-
tion to the improvement of the survival of the breast
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does seem to be important for local control [18]. Radi-
ation therapy followed by mastectomy has been previ-
ously reported to contribute to a better survival rate in
patients with breast cancer who have more than four
positive lymph nodes [19]. These factors may have been
associated with the survival of the present patient. As
for the endocrine therapy, the age of this patient was
around 40 years old, and considering the number of
axillary lymph node metastases, ovarian suppressive
function using luteinizing hormone-releasing hormone
(LH-RH) agonist might be suitable for this case. This
patient was premenopausal before starting chemother-
apy; however, the chemotherapy-induced amenorrhea
occurred during chemotherapy. There were no data
that show the superiority of the tamoxifen plus LH-RH
agonist compared to tamoxifen alone after chemother-
apy for females older than 40 years of age [20]. There-
fore, we did not introduce the LH-RH agonist for this
patient. Tamoxifen was given for 5 years as the stand-
ard method at that time, although the Adjuvant Tam-
oxifen: Longer Against Shorter (ATLAS) trial showed
that the clinical outcome of 10 years’ intake was better
than 5 years’ intake in recurrence and mortality, par-
ticularly after 10 years [21].
On the other hand, the intrinsic subtype is also con-
sidered to be an important prognostic factor [22,23].
The prognosis of the luminal A type breast cancer is
excellent compared with HER2 positive and triple nega-
tive breast cancers. In IMPC, ER positivity has also
been demonstrated to be related to a good prognosis
[24]. In our case, the tumor was positive for the ER,
and negative for the PgR and HER2. The Ki-67 labeling
index was only 4.3%. From these IHC markers, this case
seems to be classified into a ‘luminal A’ type breast can-
cer according to the St Gallen International Expert
Consensus, 2011 [25]; although Prat et al. recently sug-
gested that ‘luminal A’ in immunohistochemical-based
definition is hormone receptor positive/HER2 negative/
Ki-67 less than 14%, and PgR more than 20% [26].
Negativity of PgR may be related to the worse progno-
sis; however, a very low Ki-67 labeling index might be
related to better prognosis. It is considered that adju-
vant chemotherapy is unnecessary for luminal A type
breast cancer without lymph metastasis [27]. However,
even when the tumor is luminal A type, chemotherapy
is considered necessary if the case is of high risk of re-
currence [26]. This case was positive for extensive axil-
lary lymph node metastasis, and the age of the patient
was young. Therefore, we decided to add the standard
adjuvant chemotherapy of anthracycline and taxane.
Further study is required for the indication of the
chemotherapy adding to the hormone therapy for the
luminal type of breast cancer.Zhao et al. reported that vascular endothelial growth
factor (VEGF)-C promotes the proliferation of peritu-
moral lymphatic vessels, and that lymphatic invasion and
lymph node metastasis are frequently induced in IMPC
[28]. In lymphatic metastasis, the cancer cells in the pri-
mary site migrate in lymphatic vessels and then adhere to
the endothelial lining, which leads to extravasation and
the formation of secondary tumor sites. MUC-1, referred
to as epithelial membrane antigen (EMA), is a heavily gly-
cosylated transmembrane glycoprotein and expressed on
the apical surface of a wide variety of epithelial cells.
MUC-1 was reported to be very important in adhesion to
endothelial lining [29]. The partial reverse cell polarity in
breast carcinoma was reported to be associated with the
decrease of immunostaining for MUC-1 and lymphatic
tumor spread [30]. We did not examine the immunostain-
ing of MUC-1; however, there may be a relationship be-
tween extensive lymph node metastasis and VEGF-C and
MUC-1.
Conclusions
At present, it can be concluded that the thorough surgical
resection, completion of standard chemotherapy and hor-
mone therapy, radiation to the chest wall and the regional
lymph node areas, and ‘luminal A’ subtype might have
contributed to the good prognosis of this patient; although
other so-far unidentified prognostic factors may also exist.
Consent
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ing images.
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